中文摘要：

目的：探讨谷胱甘肽S转移酶π（GST-π）在弥漫性大B细胞淋巴瘤（Diffuse large B cell lymphoma,DLBCL）组织中的表达状况及其与临床特征和疗效的关系.方法：采用免疫组织化学方法检测63例初治DLBCL患者肿瘤组织中GST-π的表达状况,分析该基因的表达状况与DLBCL临床特征、疗效等的关系.结果：GST-π在不同性别、年龄、B症状、结外病变间表达率差异无统计学意义（P＞0.05）,各临床分期GST-π表达率为Ⅰ期55.6％、Ⅱ期58.3％、Ⅲ期64.3％、Ⅳ期75.0％,各分期间比较差异无统计学意义（P＞0.05）;不同国际预后指数（IPI） GSTπ表达率为低危组61.1％、中低危组70.6％、高中危组70.6％、高危组63.7％,各组间比较差异无统计学意义（P＞0.05）;GST-π表达阳性组和阴性组,初治完全缓解（CR）率为28.6％ vs 66.7％,总有效（RR）率为47.6％ vs 90.5％,GS-Tπ表达阳性组CR率及RR率显著低于GST-π表达阴性组（P＜0.05）.结论：GST-π表达与性别、年龄、B症状、结外病变、临床分期、IPI无相关;近期疗效GST-π阴性组优于阳性组.

英文摘要：

Objective：To explore the relationship between expression levels and clinicopathological features of GST-π in diffuse large B cell lymphoma （DLBCL） tissue. Methods： Immunohistochemistry was used to detect the expression status of 63 cases of newly diagnosed patients with DLBCL tumor tissue GST-π, and analyze the relationship between gene expression and the status of the DLBCL stage of disease, efficacy and so on. Results： GST-π expression in different subgroups of gender, age, B symptoms, extranodal lesions of DLBCL was similar （P 〉0.05）. GST-π expression rate in Ⅰ to Ⅳ stages of DLBCL was 55.6%, 58.3%, 64.3% and 75.0% （P 〉0.05）; respectively. GST-π expression rate in the low, middle-low, middle-high, and high risk groups of international prognostic index （IPI） was 61.1%, 70.6%, 70.6% and 63.7% （ P 〉0.05） ; respectively. The complete remission rate and total effective rate in GST-π positive and negative groups was 28.6% vs. 66.7% and 47.6% vs. 90. 5% （ P 〈0.05） ; respectively. Conclusion： The expression of GST-π in DLBCL was not related to different clinical stage and IPI index, but the shortterm efficacy was better in GST-π negative than in GST-π positive groups.